News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results

PDF Berlin (Germany) and San Diego, CA (U.S.A.), November 7, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced its financial results for the third quarter and the nine months 2018 ending September 30. Recent operational highlights -In September 2018, U.S. Congress urged the Centers of Medicare & Medicaid Services (CMS) to […]

Read more

Epigenomics AG Announces Veterans Administration’s Adherence Study using Epi proColon® Colorectal Cancer Screening Blood Test

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 31, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced the Veterans Administration – New York Harbor Healthcare System (VA-Manhattan) is commencing a study to assess the adherence impact of offering a blood-based colorectal cancer screening test and colonoscopy completion in patients who have refused […]

Read more

Epigenomics AG obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection

PDF – CE Mark for liver cancer blood test enables commercialization in Europe – Prospective U.S. trial for FDA submission to be initiated in 2019 – Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), October 29, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that it […]

Read more

Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon®

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 22, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rate of $192 for Epi proColon, the first and only FDA-approved blood test for colorectal cancer screening. This announcement confirms the […]

Read more

Epigenomics AG: Capital increase through rights issue with subscription rights of existing shareholders

PDF NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA. Epigenomics AG: Capital increase through rights issue with subscription rights of existing shareholders -Issuance of up to 12,007,180 new shares -Shareholders granted subscription rights at a ratio of 2:1 -Subscription price will be […]

Read more

Epigenomics AG: U.S. Congress supports CMS coverage of colorectal cancer screening blood tests

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 2, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the U.S. Congress urges the Centers of Medicare & Medicaid Services (CMS) to consider coverage of colorectal cancer screening blood tests as part of the approved 2019 Health and Human Services (HHS) […]

Read more
...